The first clinical study was published in the Journal of Applied Microbiology. The results indicated that SynForU™-HerCare is efficient in reducing vulvovaginal symptoms and recurrent vaginal candidiasis (VC) in pregnant women. The product is designed to improve the quality of life in pregnant women with VC, one of the most common health issues globally. SynForU™-HerCare is a combination of six probiotic strains isolated from dairy; Lactobacillus plantarum LP115, Lactobacillus helveticus, LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, and Lactobacillus delbrueckii subspecies lactis LDL114. The blend has been tested to ensure quality, performance, and efficacy. It is also superior in adhesive ability to Hela cell, hydrogen peroxide production, and antibacterial activity than other personal care probiotics.
Most research on probiotics and vaginal candidiasis (VC) primarily emphasized women in general, without specifically targeting pregnant women. While VC may occur randomly in pregnant women, studies indicate a higher prevalence in pregnant women regardless of their age, trimester, parity, occupation, and educational levels. Studies suggest that probiotics are the preferred option for VC treatment than antifungal drugs that usually come with side effects such as increased recurrence rate and drug resistance. “We developed further randomized studies to investigate the potential impact of probiotics on prevention of VC particularly in pregnant women.” Said Dr. San Land Young, Human Healthcare Global Operation Head of SynbioTech.
Seventy-eight participants at 14-32 weeks of pregnancy with VC took part in the double-blind, placebo-controlled randomized 8-week study. The intervention group was given lactobacilli probiotics (for eight weeks). The lactobacilli group indicated a 45% decrease in vulvovaginal symptoms such as discharge, irritation, and burning sensation. They also had a 31% reduction of worry and a 34.6% decrease of impairment of daily activities attributed to VC at week 8.
On the other hand, the placebo group showed no substantial changes in emotional stress or social impacts. Notably, the lactobacilli group also showed a 38% decrease in the recurrences of emotional stress at week eight and a 33% enhancement of the social effects compared to the placebo group. Furthermore, the lactobacilli group showed increased defecation times per week and demonstrated less constipation when compared to the placebo group.
The findings indicate that supplementation of SynForU™-HerCare decreases vulvovaginal symptoms, recurrence of VC and improves emotional and social distress caused by VC. Moreover, the supplement showed potential benefits of reducing pregnancy-induced constipation. SynForU™-HerCare is now available for worldwide distribution. Lisa Chen, Marketing Manager at Human Healthcare, SynbioTech, explained that “There are many probiotics with claims in the market, but science is the key. SynForU™-HerCare is backed by robust science, and it is our commitment to providing long-term care for women around the globe, thereby making a difference in their life”.
